Confused About the DIAN-TU Trial Data? Experts Discuss
At the virtual AAT-AD/PD Focus meeting, clinicians and funders involved in the DIAN-TU Trial discuss results from the first DIAN-TU treatment trial
At the virtual AAT-AD/PD Focus meeting, clinicians and funders involved in the DIAN-TU Trial discuss results from the first DIAN-TU treatment trial
While science groups worldwide are grappling with the logistics of shutting down to comply with the social distancing required to slow the spread of COVID-19, neurodegenerative disease researchers are asking how they can help. And help they can.
Details from the first Tau2020 Conference held in Washington, D.C. last month, shared from the Alz Forum.
The notorious amyloid precursor protein, central to Alzheimer’s disease pathogenesis, sports a new look on Alzforum’s Mutations database.
Researchers led by Marco Colonna and Maxim Artyomov at Washington University School of Medicine in St. Louis report distinct transcriptional changes in several cell types in human AD brains compared with those of 5XFAD mice.
In the year just past, Alzheimer’s researchers, families, and stakeholders felt renewed hope that new treatments might be within grasp. This update from the Alz Forum summarises how some of the increased funding might be spent.
Though Aβ-targeted therapies hogged the limelight at this year’s CTAD Conference a large handful of smaller studies had findings to report, as well.
Paper report that age-related cracks in the blood-brain barrier allow an influx of serum protein albumin into the brain, where they activate TGFβ receptors, overexcite neuronal networks, and impairing cognition.
For brain cells, what do aging, living in white matter, and hanging out with tumors have in common?
GV-971, aka oligomannate, receives conditional approval in China for the treatment of mild to moderate Alzheimer’s disease.
A multi-institutional group, including members of the Tau Consortium, unveiled a stem cell tool kit for scientists studying primary tauopathies.
The human brain follows a typical ageing trajectory, but diseased brains are further along, according to a paper in the September 24 Nature Neuroscience.
Get all the support you need sent straight to your inbox. Research news, oppertunities, blogs, podcasts, jobs, events, funding calls and much more – every friday!